Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 18 | 2021 | 108 | 2.320 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 52 | 1.420 |
Why?
|
| Immunoglobulin G | 8 | 2022 | 92 | 1.360 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2018 | 19 | 0.970 |
Why?
|
| Antibody Formation | 2 | 2022 | 18 | 0.960 |
Why?
|
| Salivary alpha-Amylases | 1 | 2023 | 3 | 0.840 |
Why?
|
| Vaccines | 1 | 2022 | 7 | 0.820 |
Why?
|
| Viral Vaccines | 1 | 2022 | 2 | 0.820 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 2017 | 7 | 0.790 |
Why?
|
| Agammaglobulinemia | 2 | 2018 | 2 | 0.750 |
Why?
|
| Common Variable Immunodeficiency | 2 | 2018 | 4 | 0.750 |
Why?
|
| Bacterial Infections | 3 | 2018 | 47 | 0.720 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 1 | 0.600 |
Why?
|
| Immunoglobulins | 1 | 2017 | 19 | 0.570 |
Why?
|
| Child, Preschool | 12 | 2019 | 652 | 0.560 |
Why?
|
| Immunologic Factors | 1 | 2017 | 33 | 0.560 |
Why?
|
| Immunotherapy | 1 | 2017 | 55 | 0.550 |
Why?
|
| Biomarkers | 6 | 2023 | 556 | 0.550 |
Why?
|
| Humans | 39 | 2023 | 26260 | 0.530 |
Why?
|
| Fluticasone | 4 | 2019 | 5 | 0.510 |
Why?
|
| Child | 12 | 2021 | 1326 | 0.470 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2019 | 101 | 0.450 |
Why?
|
| Glucocorticoids | 4 | 2019 | 58 | 0.440 |
Why?
|
| Precision Medicine | 3 | 2021 | 28 | 0.400 |
Why?
|
| Respiratory Sounds | 2 | 2019 | 9 | 0.380 |
Why?
|
| Bronchodilator Agents | 3 | 2019 | 18 | 0.360 |
Why?
|
| Female | 22 | 2021 | 14520 | 0.360 |
Why?
|
| Male | 21 | 2021 | 14168 | 0.350 |
Why?
|
| Adolescent | 9 | 2019 | 2172 | 0.340 |
Why?
|
| Adult | 13 | 2021 | 7516 | 0.340 |
Why?
|
| Salmeterol Xinafoate | 2 | 2019 | 3 | 0.330 |
Why?
|
| Alendronate | 2 | 2019 | 7 | 0.320 |
Why?
|
| Ibuprofen | 2 | 2021 | 12 | 0.320 |
Why?
|
| NF-kappa B | 3 | 2022 | 114 | 0.290 |
Why?
|
| Middle Aged | 10 | 2021 | 8541 | 0.290 |
Why?
|
| Double-Blind Method | 9 | 2021 | 411 | 0.290 |
Why?
|
| Young Adult | 6 | 2019 | 1948 | 0.280 |
Why?
|
| Saliva | 2 | 2023 | 49 | 0.280 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2018 | 17 | 0.270 |
Why?
|
| Administration, Inhalation | 7 | 2019 | 31 | 0.260 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 19 | 0.250 |
Why?
|
| Eosinophilia | 2 | 2017 | 35 | 0.220 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2003 | 2 | 0.220 |
Why?
|
| Cockroaches | 1 | 2003 | 2 | 0.220 |
Why?
|
| Allergens | 1 | 2003 | 14 | 0.220 |
Why?
|
| Acetaminophen | 3 | 2021 | 23 | 0.210 |
Why?
|
| Nucleocapsid | 1 | 2022 | 2 | 0.210 |
Why?
|
| Neutralization Tests | 1 | 2022 | 10 | 0.210 |
Why?
|
| beta-Glucans | 1 | 2022 | 24 | 0.200 |
Why?
|
| Sputum | 2 | 2019 | 21 | 0.200 |
Why?
|
| Health Personnel | 1 | 2022 | 102 | 0.190 |
Why?
|
| Pandemics | 2 | 2021 | 240 | 0.190 |
Why?
|
| Infant | 6 | 2018 | 541 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2019 | 1665 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2021 | 56 | 0.180 |
Why?
|
| Lung | 2 | 2019 | 148 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2021 | 1801 | 0.170 |
Why?
|
| Hypersensitivity | 1 | 2020 | 40 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 34 | 0.170 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 3 | 0.170 |
Why?
|
| Tiotropium Bromide | 1 | 2019 | 1 | 0.160 |
Why?
|
| Mometasone Furoate | 1 | 2019 | 8 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 303 | 0.160 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 3 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 70 | 0.160 |
Why?
|
| Eosinophils | 1 | 2019 | 38 | 0.160 |
Why?
|
| Vitamin A Deficiency | 1 | 2018 | 1 | 0.160 |
Why?
|
| Vitamin A | 1 | 2018 | 8 | 0.160 |
Why?
|
| Contrast Sensitivity | 1 | 2018 | 7 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1295 | 0.160 |
Why?
|
| Zinc | 1 | 2018 | 31 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 16 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 80 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 84 | 0.150 |
Why?
|
| Glutathione | 1 | 2018 | 21 | 0.150 |
Why?
|
| Arginine | 1 | 2018 | 15 | 0.150 |
Why?
|
| HIV Infections | 1 | 2022 | 480 | 0.140 |
Why?
|
| Leukotriene Antagonists | 1 | 2016 | 1 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3285 | 0.130 |
Why?
|
| Inhalation Exposure | 2 | 2008 | 5 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2022 | 825 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 473 | 0.130 |
Why?
|
| Azithromycin | 1 | 2015 | 2 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 25 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2015 | 52 | 0.120 |
Why?
|
| Research Design | 3 | 2021 | 190 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2014 | 6 | 0.110 |
Why?
|
| Vitamins | 1 | 2014 | 19 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 10 | 0.110 |
Why?
|
| Recurrence | 3 | 2016 | 288 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 853 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 362 | 0.100 |
Why?
|
| Quality of Life | 1 | 2017 | 606 | 0.100 |
Why?
|
| Cotinine | 2 | 2011 | 4 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 330 | 0.100 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2023 | 9 | 0.100 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2011 | 4 | 0.090 |
Why?
|
| Pruritus | 1 | 2011 | 9 | 0.090 |
Why?
|
| Silicones | 1 | 2011 | 10 | 0.090 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 25 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 24 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2011 | 28 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1722 | 0.090 |
Why?
|
| Inflammation | 2 | 2022 | 264 | 0.080 |
Why?
|
| Smoking | 1 | 2011 | 164 | 0.080 |
Why?
|
| Prevalence | 2 | 2018 | 441 | 0.080 |
Why?
|
| Aged | 3 | 2018 | 8595 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 59 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 6 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2021 | 567 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2019 | 63 | 0.070 |
Why?
|
| Albuterol | 2 | 2018 | 15 | 0.070 |
Why?
|
| Models, Biological | 1 | 2008 | 292 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 875 | 0.060 |
Why?
|
| Quinolines | 1 | 2005 | 7 | 0.060 |
Why?
|
| Acetates | 1 | 2005 | 16 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 709 | 0.060 |
Why?
|
| Air Pollution, Indoor | 1 | 2003 | 2 | 0.060 |
Why?
|
| Pyroglyphidae | 1 | 2003 | 2 | 0.060 |
Why?
|
| Skin Tests | 1 | 2003 | 8 | 0.060 |
Why?
|
| Cats | 1 | 2003 | 29 | 0.050 |
Why?
|
| Urban Health | 1 | 2003 | 22 | 0.050 |
Why?
|
| Child Welfare | 1 | 2003 | 20 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 107 | 0.050 |
Why?
|
| Dogs | 1 | 2003 | 179 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2022 | 417 | 0.050 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2022 | 1 | 0.050 |
Why?
|
| Hepatitis B e Antigens | 1 | 2022 | 1 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 46 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 6 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 47 | 0.050 |
Why?
|
| Syk Kinase | 1 | 2022 | 9 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 46 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chemokines | 1 | 2002 | 18 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 9 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 21 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2021 | 25 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2021 | 55 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 106 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 9 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 18 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 16 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 6 | 0.050 |
Why?
|
| Receptors, Fc | 1 | 2021 | 9 | 0.050 |
Why?
|
| Complement Activation | 1 | 2021 | 10 | 0.050 |
Why?
|
| United States | 2 | 2018 | 2043 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2021 | 35 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 17 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2021 | 40 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 180 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2014 | 105 | 0.040 |
Why?
|
| Education, Distance | 1 | 2020 | 15 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 32 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 27 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 12 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 1034 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 683 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 68 | 0.040 |
Why?
|
| Ornithine | 1 | 2018 | 1 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 1 | 0.040 |
Why?
|
| Growth | 1 | 2018 | 6 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 16 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 675 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 8 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 10 | 0.030 |
Why?
|
| Chicago | 2 | 2011 | 857 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 89 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 34 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 160 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 3551 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 305 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 47 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 154 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 158 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 676 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 380 | 0.030 |
Why?
|
| Patch Tests | 1 | 2011 | 2 | 0.020 |
Why?
|
| Exanthema | 1 | 2011 | 11 | 0.020 |
Why?
|
| Morbidity | 1 | 2011 | 49 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 249 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2009 | 20 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 11 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 5 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 146 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 279 | 0.020 |
Why?
|
| Sulfides | 1 | 2005 | 10 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2005 | 12 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 15 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 67 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2002 | 14 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2002 | 9 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 115 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 64 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 33 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 70 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 546 | 0.010 |
Why?
|